Kirsty

Insulin Aspart, the active ingredient in Kirsty, is an insulin analog presented as a solution for intravenous and subcutaneous use. It is employed to manage blood glucose levels in individuals with diabetes mellitus, providing rapid‑acting insulin action after injection. Its pharmacologic profile mimics endogenous insulin, facilitating glucose uptake in peripheral tissues and suppressing hepatic glucose production.

GNH USA supplies Kirsty as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Insulin Aspart is a rapid‑acting insulin analog used within the diabetes mellitus therapeutic area. - Diabetes mellitus type 1: provides prompt post‑prandial glucose control to match carbohydrate intake. - Diabetes mellitus type 2: used as part of intensive insulin regimens to achieve target glycaemic levels. - Gestational diabetes: offers rapid insulin action to control maternal hyperglycaemia during pregnancy.

Insulin Aspart may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, often presenting with sweating, tremor, or confusion. - Injection‑site reactions: redness, swelling, or itching at the administration site. - Weight gain: increase in body weight associated with improved glycaemic control. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections. - Nausea: occasional feeling of queasiness after dosing. - Headache: mild to moderate head discomfort.

Serious or Rare Side Effects: - Severe hypoglycaemia: profound low glucose requiring assistance. - Allergic reaction: rash, urticaria, or angio‑edema. - Anaphylaxis: life‑threatening systemic hypersensitivity. - Hypokalemia: low serum potassium levels. - Edema: peripheral swelling due to fluid retention. - Acute insulin resistance: unexpected loss of insulin efficacy.

Insulin Aspart requires careful clinical monitoring and patient education. - Blood‑glucose monitoring: frequent checks to adjust dose and avoid hypoglycaemia. - Renal impairment: dose may need reduction in patients with decreased kidney function. - Pregnancy: use only if benefits outweigh potential risks; consult obstetric specialist. - Hypoglycaemia history: avoid initiating therapy during an active low‑glucose episode. - Injection‑site rotation: change sites to minimise lipodystrophy. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insulin Aspart can interact with several drug classes, altering its efficacy or safety.

Major Interactions (Avoid): - Sulfonylureas: additive hypoglycaemic effect, may cause severe low blood glucose. - MAO‑inhibitors: unpredictable potentiation of insulin action. - Beta‑blockers: mask hypoglycaemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose adjustment. - Thiazide diuretics: can increase blood glucose, potentially reducing insulin effectiveness. - Oral contraceptives: may alter insulin requirements during hormonal changes. - Corticosteroids: raise glucose levels, possibly necessitating higher insulin doses.